Company intelligence / Profile preview
Empire Discovery Institute
- Ownership
- Private
- Employees
- ~25
- Development stage
- Preclinical
Overview
EDI supports early-stage drug discovery projects originating from its partner institutions, advancing them through preclinical optimization toward clinical readiness. Notably, it has received funding for small molecule remyelination agents for MS that are currently in the optimization/preclinical phase. No reported clinical trial results or commercialized drugs as of June 2025.
- Therapeutic areas
- OncologyCardiovascularNeurologyHematology
- Modalities
- Small molecule
- Industry
- Biotech
Drug pipeline
16 assets15 more assets in the full pipeline.
Request access →Partnerships
Beyond the preview
Go deeper on Empire Discovery Institute.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Empire Discovery Institute.